A new vaccine for tuberculosis, the first in 100 years, could save 8.5 million lives.
The vaccine, which has been in the works for years, has received funding of USD 550 million — from the Bill & Melinda Gates Medical Research Institute, and the global charitable organisation, Wellcome — to conduct final, phase 3 clinical trial.
Developed by GlaxoSmithKline, M72/AS01E, the new TB vaccine, proved to be 50 percent effective in the phase 2b trials that were conducted in 2018.